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Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as an urgent public health
threat. Intestinal colonization with CRE has been identified as a risk factor for the develop-
ment of systemic CRE infection, but has not been compared to colonization with third and/or
fourth generation cephalosporin-resistant (Ceph-R) Enterobacteriaceae. Moreover, the risk
conferred by colonization on adverse outcomes is less clear, particularly in critically ill
patients admitted to the intensive care unit (ICU).
Methods
We carried out a cohort study of consecutive adult patients screened for rectal colonization
with CRE or Ceph-R upon ICU entry between April and July 2013. We identified clinical vari-
ables and assessed the relationship between CRE or Ceph-R colonization and subsequent
systemic CRE infection within 30 days (primary outcome) and all-cause mortality within 90
days (secondary outcome).
Results
Among 338 ICU patients, 94 (28%) were colonized with either Ceph-R or CRE. 26 patients
developed CRE infection within 30 days of swab collection; 47% (N = 17/36) of CRE-colo-
nized and 3% (N = 2/58) of Ceph-R colonized patients. 36% (N = 13/36) of CRE-colonized
patients died within 90 days compared to 31% (N = 18/58) of Ceph-R-colonized and 15%
(N = 37/244) of non-colonized patients. In a multivariable analysis, CRE colonization inde-
pendently predicted development of a systemic CRE infection at 30 days (aOR 10.8, 95%
CI2.8–41.9, p = 0.0006); Ceph-R colonization did not (aOR 0.5, 95% CI0.1–3.3, p = 0.5).
CRE colonization was associated with increased 90-day mortality in a univariable analysis
(p-value 0.001), in a multivariable model, previous hospitalization and medical ICU







Citation: McConville TH, Sullivan SB, Gomez-
Simmonds A, Whittier S, Uhlemann A-C (2017)
Carbapenem-resistant Enterobacteriaceae
colonization (CRE) and subsequent risk of infection
and 90-day mortality in critically ill patients, an
observational study. PLoS ONE 12(10): e0186195.
https://doi.org/10.1371/journal.pone.0186195
Editor: Chiara Lazzeri, Azienda Ospedaliero
Universitaria Careggi, ITALY
Received: July 21, 2017
Accepted: September 27, 2017
Published: October 12, 2017
Copyright: © 2017 McConville et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The Columbia
University Medical Center Institutional Review
Board has placed restrictions on sharing the data
underlying this study to protect participant privacy.
The restricted data will be available upon request to
researchers who are qualified to access
confidential patient information. Data access
requests may be sent to rascal@columbia.edu.
Data cannot be made publicly available for ethical
or legal reasons, e.g., public availability would
admission were independent predictors of 90-day mortality whereas CRE colonization
approached significance (aOR 2.3, 95% CI1.0–5.3, p = 0.056).
Conclusions
Our study highlights the increased risk of CRE infection and mortality in patients with CRE
colonization at the time of ICU admission. Future studies are needed to assess how CRE
colonization can guide empiric antibiotic choices and to develop novel decolonization
strategies.
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) have become widespread in the US, prom-
pting the Centers for Diseases Control and Prevention (CDC) to classify them as an urgent
threat to public health, its highest risk category [1]. CRE infections account for an estimated
140,000 cases of healthcare-associated infections annually [1], and produce high attributable
mortality rates of 26–44% [2]. Infections with CRE disproportionately affect severely ill
patients with multiple comorbidities [3]. Patients residing in the intensive care unit (ICU)
have been found to have a particularly high burden of CRE infections as well as increased mor-
tality [4–6]. Immunocompromised patients, organ transplant recipients, and patients with pre-
vious antibiotic exposure and central venous catheters are also at increased risk of infection
with CRE [7–9].
The majority of CRE infections worldwide are caused by K. pneumoniae. Recently, carbape-
nem resistance has also been increasingly reported in Escherichia coli, Klebsiella oxytoca, and
Enterobacter cloacae [10, 11]. One of the potential endogenous reservoirs of CRE is the human
intestine, where Enterobacteriaceae, including K. pneumoniae, can reside as colonizers. In
endemic areas, the prevalence of CRE colonization in hospitalized patients ranges from 3–7%
[12–17], but can be higher in patients admitted to intensive care units (ICU) [5]. Colonization
with CRE is a known risk factor for subsequent CRE infections. In a recent meta-analysis of
1,806 patients colonized with CRE, the overall risk of systemic CRE infection was 16.5% [6]. In
ICU patients, this risk varied widely and between 29–73% of carbapenem-resistant K. pneumo-
niae carriers subsequently developed infections [4, 5]. Mortality in ICU CRE carriers was high
and ranged between 26 to 41% [5, 18, 19]. However, variability in CRE organisms, study popu-
lation and study design (e.g. outbreak versus endemic setting) have allowed limited conclu-
sions about the clinical importance and utility of identifying CRE carriers. Screening for
resistant Gram-negative (CRE, Ceph-R) intestinal carriage is not the universal standard of
care, although some experts advocate surveillance during outbreaks as part of infection control
initiatives [10, 20]. While Ceph-R colonization has similar risk factors and is associated with
increased use of broad-spectrum antibiotics [21] the role of colonization with third and/or
fourth generation cephalosporin-resistant Enterobacteriaceae (Ceph-R) on subsequent CRE
infections is less clear.
As part of a non-outbreak surveillance initiative at our institution located in an area of high
CRE endemicity, rectal screening was performed in medical and surgical ICUs to identify car-
riage with CRE Ceph-R. Here, we examined the rates of fecal colonization with CRE and/or
Ceph-R at the time of ICU admission and determined the risk of 30-day CRE infection (pri-
mary outcome) and all-cause mortality at 90 days post ICU admission (secondary outcome).
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PLOS ONE | https://doi.org/10.1371/journal.pone.0186195 October 12, 2017 2 / 14
compromise patient confidentiality or participant
privacy.
Funding: This work was supported by grants from
the National Institutes of Health/National Institute
of Allergy and Infectious Diseases R01 AI116939
(ACU). The funders had no role in study design,
data collection and interpretation, or the decision to
submit the work for publication. ACU has received
research funding from Merck, unrelated to the
current study. This does not alter our adherence to
PLOS ONE policies on sharing data. All other
authors declare no conflict of interest.
Competing interests: Dr. Uhlemann reports
receiving grant funding from Merck, unrelated to
the current study. This does not alter our




This was an observational cohort study performed at a large academic medical center and an
affiliated community hospital in Northern Manhattan. The Columbia University Medical Cen-
ter (CUMC) institutional review board approved this study (IRB AAAM 6617) and waived the
need for informed consent. We included all patients>18 years old who had undergone evalua-
tion for rectal colonization with multi-drug resistant (MDR) Gram-negative organisms on
admission to one of the adult medical ICUs (MICU) or surgical ICUs (SICU) between April
7th 2013 to July 8th 2013. During this 3-month period rectal swabs (BD CultureSwab, Becton,
Dickinson) from 338 patients collected at the time of admission to the four intensive care units
at our center were processed by the clinical microbiology laboratory. Collected samples were
streaked onto Remel Spectra Chromogenic Agar (Remel). Positive colonies were tested for spe-
cies identification and drug susceptibilities using VITEK according to the CLSI guidelines
[22]. CRE were designated on the basis of meropenem minimum inhibitory concentration
(MIC) 2 μg/ml or ertapenem MIC1 μg/ml. Gram-negative bacteria not belonging to fam-
ily Enterobacteriaceae were also identified using this approach. Isolates that were carbapenem
susceptible but exhibited third and/or fourth generation cephalosporin resistance, were desig-
nated Ceph-R.
We extracted demographic and clinical information from the patient’s electronic charts,
including ICU admission diagnosis, prior hospital admissions or transfer from a nursing
home/long-term care facility over the past 6 months, and antibiotic exposure in the inpatient
setting within the past 6 months. The Charlson Comorbidity Index score (CCIS) was calcu-
lated from clinical data as a marker of patients’ underlying health [23]. Charts were also
reviewed for both previous positive cultures with CRE over the 6 months prior to ICU admis-
sion and for subsequent development of infections with these organisms for up to 90 days fol-
lowing ICU admission and swab collection. Previous positive cultures represented blood,
respiratory, wound, or urine cultures positive for CRE. Subsequent infections were classified
based on positive clinical cultures and meeting NHSN criteria for infections [24]. All patients
were assumed to receive standard ICU level care, including, but not limited to standard isola-
tion precautions and ventilator bundles when intubated. Notably, Surveillance results were not
available to the treating physicians at the time of culture and thus did not factor into clinical
decisions including isolation precautions and antibiotic management.
Statistical analysis
Patients were categorized according to results of screening for rectal colonization on ICU
admission as CRE-colonized, Ceph-R-colonized or non-colonized. Clinical parameters were
described as frequencies or using the median and interquartile range (IQR). In an analysis of
factors associated with primary and secondary outcomes, variables between groups were com-
pared using χ2 or Fisher’s exact test for categorical variables and unpaired t-test or Mann-
Whitney-Wilcoxon test for continuous variables as appropriate. Variables with a p-value
<0.05 were considered for inclusion in a multivariable logistic model. Variables that were
strongly correlated with variables already included in the model were left out of the analysis
(i.e. admission diagnosis and ICU type). Other variables (i.e. gender, age, CCIS, and ICU type)
were included a priori as they were considered potential confounders. As part of the multivari-
able logistic model for 90 day mortality a mediation analysis was performed for CRE infection
given the causal hypothesis that CRE colonization increases risk for subsequent CRE infection
and as a result mortality.
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The primary outcome measure in this study was the development of CRE infection within
30 days of the positive swab. Our secondary outcome measure was 90-day mortality from the
date of swab collection. Additional analyses were performed using survival analysis methods.
Specifically, the relationship between CRE and/or Ceph-R colonization and both the primary
and secondary outcomes was analyzed using Kaplan-Meier curves and the log-rank test. In the
analysis of infection within 30 days, patients who died were censored. Data were analysed
using SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
Clinical characteristics of ICU patient cohort
The study population encompassed 103 SICU and 235 MICU patients who were screened for
fecal colonization upon entry to the ICU. Study participants (n = 338) were predominantly
male (n = 184, 54%) with an average age of 63 years (range 19–95) at the time of ICU admis-
sion (Table 1). Thirty-six patients (11%) were colonized with CRE. The majority of these were
accounted for by K. pneumoniae (n = 33, 92%, Table 1). The CRE screening test also revealed
the presence of colonization with Ceph-R Enterobacteriaceae in 58 patients (Table 1). The
majority of Ceph-R isolates were E. coli (n = 39, 67%) followed by K. pneumoniae (n = 9, 16%).
Characteristics of CRE-colonized, Ceph-R-colonized, and non-colonized patients are sum-
marized in Table 1. Patients colonized with either CRE and/or Ceph-R were significantly more
likely than non-colonized patients to have a recent hospitalization or subacute nursing facility
(SNF) admission, underlying liver disease, history of solid organ transplantation (SOT), and
antibiotic exposure within the past 6 months, except to 1st or 2nd generation cephalosporins,
trimethoprim-sulfamethoxazole and macrolides (Table 1). Overall, colonized and non-colo-
nized groups did not significantly differ by age, gender, ICU admission diagnosis including
septic shock, CCIS or ICU location (Table 1).
CRE-colonized patients had significantly higher rates of liver disease compared to non-col-
onized patients (Bonferroni-corrected p = 0.0006). Ceph-R-colonized patients more often had
heart disease compared to non-colonized patients (Bonferroni-corrected p = 0.02; Table 1). All
CRE-colonized patients and 97% of Ceph-R-colonized patients had received antibiotic therapy
within the past 6 months, compared to 71% of non-CRE colonized patients (Table 1). This
included exposure to carbapenems in nearly one third of the CRE-colonized group. It is nota-
ble that in the 6 months prior to swab collection, 19 (53%) CRE-colonized patients had a previ-
ous CRE infection and 9 (25%) were infected with a Ceph-R (Table 1). Ceph-R-colonized
patients had a similarly high rate of previous Ceph-R infections (n = 22, 38%). Among Ceph-R
and non-colonized patients, previous CRE infections were uncommon (n = 3, 5%; n = 2, 1%;
respectively).
Characteristics of CRE infections
CRE infections developed in 26 patients (8%) within 30 days and 32 (9%) patients within 90
days. Pneumonia was the most common type of infection occurring within 30 days (n = 23,
88%), followed by urinary tract infections (n = 5, 19%). Four patients developed bloodstream
infections (15%) and two had wound and intra-abdominal infections (8%). There were 9
patients with infections at multiple sites (35%).
Of 36 CRE-colonized patients, 17 (47%) developed a CRE infection within 30 days and 19
(53%) within 90 days of swab collection. Seven patients (19%) who were CRE-colonized subse-
quently developed infection with a Ceph-R organism. In Ceph-R-colonized patients, Ceph-R
infection occurred in 13 (22%) patients within 30 days of swab collection, which was higher
than the number of infections seen in the non-colonized group (n = 9, 4%), but comparable to
CRE colonization and infection in ICU patients
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Table 1. Baseline characteristics of intensive care unit study population.
Variable
n (%)














Male sex 30 (52%) 21 (58%) 51 (54%) 133 (55%) 1.0 0.1
Age > 65 years 32 (55%) 18 (50%) 50 (53%) 112 (46%) 0.2 0.4
Admitted From 0.0002 <0.0001
Home 42 (72%) 20 (56%) 62 (66%) 209 (86%)
SNF or Group Home 9 (16%) 14 (39%) 23 (24%) 22 (9%)
Outside Hospital 7 (12%) 2 (6%) 9 (10%) 13 (5%)
ICU Type 0.3 0.2
Surgical 12 (21%) 13 (36%) 25 (27%) 78 (32%)
Medical 46 (79%) 23 (64%) 69 (73%) 166 (68%)
ICU Admission Diagnosis 0.2 0.5
Surgery 13 (22%) 10 (28%) 23 (24%) 83 (34%)
Shock 20 (34%) 13 (36%) 33 (35%) 68 (28%)
Respiratory Failure 18 (31%) 8 (22%) 26 (28%) 53 (22%)
Metabolic Disarray 5 (9%) 3 (8%) 8 (9%) 18 (7%)
Altered Mental Status 2 (3%) 2 (6%) 4 (4%) 22 (9%)
CCIS (mean, IQR) 3 (2,4) 3 (2,4) 3 (2,4) 3 (1,4) 0.2 0.4
Type II DM 21 (36%) 7 (19%) 28 (30%) 79 (32%) 0.7 0.2
Heart Disease 11 (19%) 1 (3%) 12 (13%) 18 (7%) 0.1 0.008
Pulmonary Disease 18 (31%) 15 (42%) 33 (35%) 66 (27%) 0.14 0.2
Liver Disease 10 (17%) 14 (39%) 24 (36%) 34 (14%) 0.01 0.001
Malignancy 11 (19%) 5 (14%) 16 (17%) 65 (27%) 0.06 0.2
Renal Disease 13 (22%) 6 (17%) 19 (20%) 48 (20%) 0.9 0.8
Previous SOT 13 (22%) 9 (25%) 22 (23%) 22 (9%) 0.0004 0.002
Within the previous 6 months
Hospitalization 39 (67%) 30 (83%) 69 (73%) 106 (43%) <0.0001 <0.0001
Endoscopies
EGD or colonoscopy 10 (17%) 11 (31%) 21 (22%) 32 (13%) 0.04 0.03
ERCP or EUS 2 (3%) 2 (6%) 4 (4%) 4 (2%) 0.2 0.1
Antibiotic Exposure 56 (97%) 36 (100%) 92 (98%) 174 (71%) <0.0001 <0.0001
Piperacillin/Tazobactam 34 (59%) 28 (78%) 62 (66%) 108 (44%) 0.0004 0.0003
Carbapenem 11 (19%) 11 (31%) 22 (23%) 11 (5%) <0.0001 <0.0001
1st or 2nd-generation cephalosporin 21 (36%) 16 (44%) 37 (39%) 77 (32%) 0.2 0.3
3rd or 4th-generation Cephalosporin 17 (29%) 14 (39%) 31 (33%) 54 (22%) 0.04 0.07
Fluoroquinolone 13 (22%) 13 (36%) 26 (28%) 42 (17%) 0.03 0.03
Aminoglycoside 18 (31%) 13 (36%) 31 (33%) 40 (16%) 0.0008 0.003
Vancomycin 34 (59%) 26 (72%) 60 (64%) 87 (36%) <0.0001 <0.0001
TMP/SMX 6 (10%) 2 (6%) 8 (9%) 12 (5%) 0.8 0.3
Tetracycline 2 (3%) 5 (14%) 7 (7%) 3 (1%) 0.001 0.001
Polymyxin 2 (3%) 4 (11%) 6 (6%) 3 (1%) 0.02 0.005
Macrolide 17 (29%) 12 (33%) 29 (31%) 51 (21%) 0.05 0.1
Previous infection
Ceph-R or CRE infection 21 (36%) 22 (61%) 43 (46%) 15 (6%) <0.0001 <0.0001
Ceph-R infection 22 (38%) 9 (25%) 31 (33%) 13 (5%) <0.0001 <0.0001
CRE infection 3 (5%) 19 (53%) 22(23%) 2 (1%) <0.0001 <0.0001
Colonizing organism
E. coli 39 (67%) 0 (0%) 39 (41%)
K. pneumoniae 9 (16%) 33 (92%) 42 (45%)
(Continued)
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the CRE colonized group (n = 7, 19%). In contrast, colonization with Ceph-R was not associ-
ated with subsequent CRE infection.
In univariable analysis, colonization status was significantly associated with development of
subsequent CRE infection. These infections occurred much more commonly in patients with
antecedent CRE colonization (n = 17, 65%) than in Ceph-R colonized (n = 2, 8%) and non-col-
onized patients (n = 7, 27%, p<0.0001). This association held when analyzed using Kaplan-
Meier estimates of the probability of remaining uninfected with CRE (Fig 1, log-rank p<
0.0001). CRE infected patients were also more likely than uninfected patients to have been
recently admitted to a hospital or SNF, undergone an endoscopic procedure, or taken antibiot-
ics within the previous 6 months; these patients also had higher rates of liver disease (Table 2).
Patients with CRE infections compared to uninfected patients also differed in prior infection
status (overall p<0.0001), as they were more likely to have a history of prior infection with car-
bapenem-resistant (n = 12, 46% versus n = 11, 4%) and Ceph-R organisms (n = 4, 15% versus
n = 31, 10%).
In the final multivariable model, after controlling for age, gender, CCIS, ICU type, prior
upper endoscopy or colonoscopy, antibiotic use, previous CRE or Ceph-R infection and hospi-
talization within the past 6 months, CRE colonization compared to non-colonization was
associated with a 10.8-fold increased odds of CRE infection at 30 days (95% CI 2.8–41.9,
p = 0.0006; Table 2). Ceph-R colonization was not significantly associated with subsequent
CRE infection. Hospitalization within the past 6 months and previous EGD or colonoscopy
were also significant predictors of 30-day CRE infection in this model.
All cause 90-day mortality after rectal swab collection
The 90-day all-cause mortality in this cohort of ICU patients was 20% (n = 68). Compared
to non-colonized patients, patients colonized with either a Ceph-R or CRE had signifi-
cantly higher mortality within 90 days of swab collection (33% versus 15%, p = 0.0003).
For CRE-colonized patients the 30-day mortality was 31% and reached 36% (n = 13) at
90-days. Ceph-R-colonized patients had 27% and 33% 30- and 90-day mortality rates,
respectively.
In univariable analysis, there was a significant difference in mortality among CRE-colo-
nized (n = 13, 36%), Ceph-R-colonized (n = 18, 31%), and non-colonized patients (n = 37,
15%; overall p = 0.001; Table 3). The Kaplan-Meier survival estimates also support this finding,
where the Ceph-R and CRE colonized groups had lower survival probabilities than the non-

















Other 10 (17%) 3 (8%) 13 (14%)
*p-value reflects a 2-way comparison between either Ceph-R- or CRE-colonized (i.e. Any colonization) and non-colonized patients
** p-value reflects a 3-way comparison between Ceph-R-colonized, CRE-colonized, and non-colonized patients
Abbreviations: Ceph-R, 3rd/4th generation cephalosporin-resistant Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; SNF, skilled
nursing facility; ICU, intensive care unit; CCIS, Charlson Comorbidity Index score; IQR, intraquartile range; DM, diabetes mellitus; SOT, solid organ
transplant; EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; TMP/SMX,
trimethoprim/sulfamethoxazole.
https://doi.org/10.1371/journal.pone.0186195.t001
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disease, CCIS, admission diagnosis, previous Ceph-R or CRE infection, hospitalization and
antibiotic use in the previous 6 months were significantly associated with 90-day mortality
(Table 3).
In a mediation analysis, we compared a simple logistic regression model containing only
Ceph-R or CRE colonization to a model also containing subsequent CRE infection within
30 days of rectal swab. In the simple model, both Ceph-R and CRE colonization were signifi-
cantly associated with 90-day mortality (OR 2.5, 95% CI 1.3–4.9; OR 3.2, 95% CI 1.5–6.8,
respectively; p = 0.001). After the addition of subsequent CRE infection, only Ceph-R coloniza-
tion remained significantly associated with 90-day mortality (Ceph-R aOR 2.5, 95% CI 1.3–4.9;
CRE aOR 1.6, 95% CI 0.6–4.2; p = 0.02). Subsequent CRE infection mediated the relationship of
colonization to 90-day mortality, but only for those individuals colonized with CRE organisms.
After adjusting for age, gender, CCIS score, ICU type, previous hospitalization, and antibi-
otic use within the previous 6 months, Ceph-R and/or CRE colonization was not a significant
predictor of 90-day mortality (p = 0.08), although CRE colonization showed a trend towards
Fig 1. Kaplan-Meier estimates (and 95% confidence limits) of the probability of remaining uninfected with CRE, 30 day follow up.
https://doi.org/10.1371/journal.pone.0186195.g001
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increase mortality (aOR 2.3, 95% CI 1.0–5.3; p = 0.056). Admission to the MICU (aOR 3.2,
95% CI 1.4–6.9, p = 0.004), CCIS score (aOR 1.2, 95% CI 1.0–1.3, p = 0.045), and hospitaliza-
tion in the past 6 months (aOR 2.3, 95% CI 1.2–4.4, p = 0.02) independently predicted 90-day
mortality in the multivariable analysis.










Male sex 169 (54%) 15 (58%) 0.7 0.8 (0.3, 2.5) 0.8
Age > 65 years 152 (49%) 10 (38%) 0.3 0.6 (0.2, 1.7) 0.4
Admitted From 0.0005
Home 258 (83%) 13 (50%)
SNF or Group Home 36 (12%) 9 (35%)
Outside Hospital 18 (6%) 4 (15%)
ICU Type 0.7 0.9
Surgical 96 (31%) 7 (27%) REF
Medical 216 (69%) 19 (73%) 1.1 (0.3, 3.5)
ICU Admission Diagnosis 0.04
Surgery 101 (32%) 5 (19%)
Shock 94 (30%) 7 (27%)
Respiratory Failure 70 (22%) 9 (35%)
Metabolic Disarray 21 (7%) 5 (19%)
Altered Mental Status 26 (8%) 0 (0%)
CCIS (mean, IQR) 3 (2,4) 3.2 (2,4) 0.9 0.9 (0.7, 1.2) 0.6
Type II DM 101 (32%) 6 (23%) 0.3
Heart Disease 28 (9%) 2 (8%) 1.0
Pulmonary Disease 88 (28%) 11 (42%) 0.1
Liver Disease 49 (16%) 9 (35%) 0.03
Malignancy 77 (25%) 4 (15%) 0.3
Renal Disease 63 (20%) 4 (15%) 0.6
Previous SOT 40 (13%) 4 (15%) 0.8
Within the previous 6 months
Hospitalization 151 (48%) 24 (92%) <0.0001 6.6 (1.3, 34.3) 0.03
Endoscopies
EGD or colonoscopy 42 (13%) 11 (42%) 0.0006 3.7 (1.2, 11.1) 0.02
ERCP or EUS 6 (2%) 2 (8%) 0.1
Antibiotic use 241 (77%) 25 (96%) 0.02 1.1 (0.1, 1.5) 0.9
Previous Ceph-R- or CRE infection <0.0001 0.2*
No previous Ceph-R or CRE infection 270 (87%) 10 (38%) REF
Previous Ceph-R infection 31 (10%) 4 (15%) 2.1 (0.5, 9.6) 0.3
Previous CRE infection 11 (4%) 12 (46%) 3.5 (0.8, 14.8) 0.08
Colonization Resistance Phenotype <0.0001 0.0003*
Non-colonized 237 (76%) 7 (27%) REF
Ceph-R colonized 56 (18%) 2 (8%) 0.5 (0.1, 3.3) 0.5
CRE colonized 19 (6%) 17 (65%) 10.8 (2.8, 41.9) 0.0006
*Global p-values for categorical variables in the multivariable model
Abbreviations: OR, odds ratio; SNF, skilled nursing facility; ICU, intensive care unit; CCIS, Charlson Comorbidity Index score; IQR, intraquartile range; DM,
diabetes mellitus; SOT, solid organ transplant; EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS,
endoscopic ultrasound; Ceph-R, 3rd/4th generation cephalosporin-resistant Enterobacteriaceae.
https://doi.org/10.1371/journal.pone.0186195.t002
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Discussion
Rectal colonization with CRE has previously been identified as an important epidemiological
risk factor for the development of subsequent CRE infection. In a recent meta-analysis, colo-
nized patients had a 16.5% cumulative infection rate [6]. However, these studies focused on a





Non-survivor (n = 68) Univariable
p-value
Adjusted OR (95% CI) Multivariable
p-value
Male sex 147 (54%) 37 (54%) 1.0 0.9 (0.5, 1.6) 0.7
Age > 65 127 (47%) 35 (51%) 0.5 1.2 (0.7, 2.1) 0.6
Admitted From 0.003
Home 226 (84%) 45 (66%)
SNF or Group Home 28 (10%) 17 (25%)
OSH 16 (6%) 6 (9%)
ICU Type 0.0005 0.004
Surgical 94 (35%) 9 (13%) REF
Medical 176 (65%) 59 (87%) 3.2 (1.4, 6.9)
ICU Admission Diagnosis 0.0002
Surgery 99 (37%) 7 (10%)
Shock 69 (26%) 32 (47%)
Respiratory Failure 61 (23%) 18 (26%)
Metabolic Disarray 19 (7%) 7 (10%)
Altered Mental Status 22 (8%) 4 (6%)
CCIS (mean, IQR) 2.8 (1, 4) 3.6 (2, 5) 0.005 1.2 (1.0, 1.3) 0.045
Type II DM 85 (31%) 22 (32%) 0.9
Heart Disease 24 (9%) 6 (9%) 1.0
Pulmonary Disease 78 (29%) 21 (31%) 0.8
Liver Disease 44 (16%) 14 (21%) 0.4
Malignancy 63 (23%) 18 (26%) 0.6
Renal Disease 47 (17%) 20 (29%) 0.03
Previous SOT 39 (14%) 5 (7%) 0.1
Within the previous 6 months
Hospitalization 123 (46%) 52 (76%) <0.0001 2.3 (1.2, 4.4) 0.02
Endoscopies
EGD or colonoscopy 40 (15%) 13 (19%) 0.4
ERCP or EUS 7 (3%) 1 (1%) 1.0
Antibiotic use 204 (76%) 62 (91%) 0.005 1.9 (0.7, 5.9) 0.2
Previous Ceph-R- or CRE infection 0.0009
No 234 (87%) 46 (68%)
Previous Ceph-R Infection 21 (8%) 14 (21%)
Previous CRE infection 15 (6%) 8 (12%)
Colonization Resistance Phenotype 0.001 0.08
Non-colonized 207 (77%) 37 (54%) REF
Ceph-R colonized 40 (15%) 18 (26%) 1.8 (0.9, 3.7) 0.09
CRE colonized 23 (9%) 13 (19%) 2.3 (1.0, 5.3) 0.056
Abbreviations: OR, odds ratio; SNF, skilled nursing facility; ICU, intensive care unit; CCIS, Charlson Comorbidity Index score; IQR, intraquartile range; DM,
diabetes mellitus; SOT, solid organ transplant; EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS,
endoscopic ultrasound; Ceph-R, 3rd/4th generation cephalosporin-resistant Enterobacteriaceae.
https://doi.org/10.1371/journal.pone.0186195.t003
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variety of clinical settings, were conducted during outbreaks and only few have focused on ICU
patients, limiting generalizability [4, 5, 14, 25–29]. In our cohort of ICU patients, we also found
CRE colonization to be a strong predictor of infection within 30 days of rectal swab collection.
Here, close to 50% of our CRE-colonized patients developed a CRE infection within 30 days,
representing a 10.8-fold increase in the odds of infection compared to non-colonized patients.
Notably, among patients colonized with CRE who went on to develop a CRE infection, the
colonizing and infecting organism were the same species in all but one patient. This may have
important implications for empiric antibiotic selection in colonized patients. Considering that
the most common infection was pneumonia, aspiration of gastrointestinal contents may be a
potential mechanism linking intestinal colonization with the development of infection in this
critically ill cohort. Previous endoscopy or colonoscopy were also a predictor for CRE infection
in the current study. Interestingly, while there have been reported outbreaks of both Ceph-R
producing bacteria and CRE related to ERCP (attributed to difficulty sterilizing endoscopes)
[30, 31], previous ERCP or EUS were not predictors of colonization in our cohort.
Fig 2. Kaplan-Meier estimates (and 95% confidence limits) of the survival probability for all-cause mortality, 90 day follow up.
https://doi.org/10.1371/journal.pone.0186195.g002
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Intriguingly, Ceph-R colonization was not significantly associated with subsequent CRE
infection at 30 days despite having nearly identical epidemiological risk factors [21]. The
overlap in risk factors between Ceph-R and CRE colonized ICU patients also suggests that the
factors contributing to CRE colonization are by themselves insufficient to produce CRE infec-
tions, and that antecedent colonization is necessary. While not significant in the multivariable
model, we noted a potential inverse relationship between Ceph-R colonization and CRE infec-
tion. This may suggest that Ceph-R organisms share a colonization niche in the gut with CRE
and that Ceph-R colonization could confer a degree of protection from CRE colonization and
subsequent infection. The host and pathogen factors that ultimately lead to the transition from
colonization to systemic infection have not been well defined.
Adverse outcomes following colonization with CRE are incompletely reported [6]. In a
pooled analysis from three studies, mortality reached 10% for colonized or infected patients
[6], but was much higher in patients who developed infection (30–75%). In a secondary analy-
sis, we examined risk factors for 90-day mortality. In the multivariable analysis, only admission
to the medical ICU, CCIS score, and previous hospitalization predicted 90-day mortality.
Interestingly, the association between Ceph-R or CRE colonization and mortality seen in the
univariate analysis was not seen in the multivariable analysis. Our study may have been under-
powered to detect a significant difference, particularly given the many potential factors con-
tributing to mortality in this ICU population.
This study had several limitations. First, in our patient population, colonization with either
CRE or Ceph-R approached 30%, and our findings might not be directly translatable to areas
with lower prevalence of Gram-negative drug resistance. Second, while 338 subjects were
included, the cohort yielded only 26 CRE infections within the first 30 days, which limited the
power of our statistical analyses. However, because the study was conducted during a 3-month
period where all patients admitted to adult ICUs were screened for intestinal colonization,
selection bias was limited. Third, rectal swabs were only obtained at the time of ICU admis-
sion. We were therefore unable to assess the impact of CRE acquisition or loss of colonization
during the ICU stay and a number of patients may have been misclassified. Fourth, we were
also unable to perform molecular typing of the isolates or to investigate bacterial factors medi-
ating transition from colonization to infection. Fifth, we did not have access to colonizing or
infecting isolates. Thus, we were we were unable to clarify the mechanism for resistance in the
CRE and Ceph-R isolates (i.e. presence of carbapenemase or ESBL genes). Additionally, we
had to rely on VITEK MIC data for these isolates, which can be unreliable at times. Future
work is needed to identify virulence factors unique to colonizing versus infecting isolates and
to identify modifiable clinical factors, e.g. use of broad-spectrum antibiotics and immunosup-
pressants, that may accelerate the transition from colonization to infection. Lastly, our second-
ary analysis was limited to all-cause, rather than attributable, mortality. Thus, we are unable to
determine whether the high mortality rates seen in the CRE-infected group were directly
attributable to their infection or were more likely to occur in patients with other fatal illnesses.
Similarly, when analyzing mortality data, we did not consider antibiotic management or other
disease management considerations, which also may have impacted outcomes.
Previous studies demonstrate the utility of rectal screening for CRE in outbreak settings to
enhance identification of patients for cohorting and other infection control measures. More
recently, several studies show improvement in outcomes following decolonization therapy.
In a recent randomized control trial by Machuca et al., subjects colonized with carbapenem-
resistant K. pneumoniae underwent decolonization therapy with an oral aminoglycoside (gen-
tamicin or neomycin/streptomycin) [32]. At 180-day follow-up, those who underwent decolo-
nization therapy had significantly lower mortality rates (HR 0.18) and rates of systemic
infection (HR 0.15) than those who did not. A similar study demonstrated success with the use
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of oral polymyxin B [32]. However, it will be critical to examine decolonization therapy on a
larger scale with particular attention to adverse outcomes, especially the emergence of further
resistance in the targeted organisms. Fecal microbial transplantation might evolve as an alter-
native, less toxic strategy to restore a healthy intestinal microbiome to eliminate CRE coloniza-
tion [33].
Conclusions
Taken together, we found that in critically ill patients, CRE colonization was associated with a
high risk of subsequent CRE infection and produced high mortality rates. This association was
not seen in Ceph-R-colonized patients. Our findings suggest that in CRE endemic areas this
screening approach may identify patients at high risk for CRE infection early and lead to early
optimization of antimicrobial treatment. Future studies are needed to test novel decoloniza-
tion strategies such as novel antimicrobial combinations or fecal microbial transplantation to
decrease the risk of infections and poor outcomes in these critically ill patients.
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